Reneo Pharmaceuticals Analyst Ratings
Reneo Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/12/2023 | 265.41% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 09/08/2023 | 265.41% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 08/28/2023 | 265.41% | HC Wainwright & Co. | → $30 | Initiates Coverage On | → Buy |
| 07/03/2023 | 180.15% | B of A Securities | → $23 | Initiates Coverage On | → Buy |
| 09/19/2022 | 277.59% | HC Wainwright & Co. | → $31 | Assumes | → Buy |
| 05/18/2022 | 119.24% | Piper Sandler | $45 → $18 | Maintains | Overweight |
| 03/24/2022 | 82.7% | SVB Leerink | $25 → $15 | Maintains | Outperform |
| 01/27/2022 | 241.05% | Baird | → $28 | Initiates Coverage On | → Outperform |
| 12/21/2021 | 241.05% | HC Wainwright & Co. | → $28 | Initiates Coverage On | → Buy |
| 11/22/2021 | 448.11% | Ladenburg Thalmann | → $45 | Initiates Coverage On | → Buy |
| 05/04/2021 | 204.51% | SVB Leerink | → $25 | Initiates Coverage On | → Outperform |
| 05/04/2021 | 192.33% | Jefferies | → $24 | Initiates Coverage On | → Buy |
| 05/04/2021 | 448.11% | Piper Sandler | → $45 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年10月12日 | 265.41% | HC Wainwright公司 | →$30 | 重申 | 购买→购买 |
| 09/08/2023 | 265.41% | HC Wainwright公司 | →$30 | 重申 | 购买→购买 |
| 2023年08月28日 | 265.41% | HC Wainwright公司 | →$30 | 开始承保 | →购买 |
| 07/03/2023 | 180.15% | B of A证券 | →$23 | 开始承保 | →购买 |
| 2022/09/19 | 277.59% | HC Wainwright公司 | →$31 | 假设 | →购买 |
| 2022/05/18 | 119.24% | 派珀·桑德勒 | $45→$18 | 维护 | 超重 |
| 03/24/2022 | 82.7% | SVB Leerink | $25→$15 | 维护 | 跑赢大盘 |
| 2022年01月27日 | 241.05% | 贝尔德 | →$28 | 开始承保 | →跑赢大盘 |
| 2021/12/21 | 241.05% | HC Wainwright公司 | →$28 | 开始承保 | →购买 |
| 2021年11月22日 | 448.11% | 拉登堡·塔尔曼 | →$45 | 开始承保 | →购买 |
| 05/04/2021 | 204.51% | SVB Leerink | →$25 | 开始承保 | →跑赢大盘 |
| 05/04/2021 | 192.33% | 杰富瑞 | →$24 | 开始承保 | →购买 |
| 05/04/2021 | 448.11% | 派珀·桑德勒 | →$45 | 开始承保 | →超重 |
What is the target price for Reneo Pharmaceuticals (RPHM)?
雷诺制药(Reneo PharmPharmticals)的目标价是多少？
The latest price target for Reneo Pharmaceuticals (NASDAQ: RPHM) was reported by HC Wainwright & Co. on October 12, 2023. The analyst firm set a price target for $30.00 expecting RPHM to rise to within 12 months (a possible 265.41% upside). 4 analyst firms have reported ratings in the last year.
雷诺制药(纳斯达克代码：RPHM)的最新目标价是由HC Wainwright&Co.于2023年10月12日报道的。这家分析公司将目标价定为30美元，预计RPHM将在12个月内上涨至(可能上涨265.41%)。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Reneo Pharmaceuticals (RPHM)?
Reneo PharmPharmticals(RPHM)的最新分析师评级是多少？
The latest analyst rating for Reneo Pharmaceuticals (NASDAQ: RPHM) was provided by HC Wainwright & Co., and Reneo Pharmaceuticals reiterated their buy rating.
分析师对雷诺制药(纳斯达克代码：RPHM)的最新评级由HC Wainwright&Co.提供，雷诺制药重申其买入评级。
When is the next analyst rating going to be posted or updated for Reneo Pharmaceuticals (RPHM)?
Reneo PharmPharmticals(RPHM)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Reneo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Reneo Pharmaceuticals was filed on October 12, 2023 so you should expect the next rating to be made available sometime around October 12, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Reneo PharmPharmticals的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Reneo制药的上一次评级是在2023年10月12日提交的，所以你应该预计下一次评级将在2024年10月12日左右的某个时候公布。
Is the Analyst Rating Reneo Pharmaceuticals (RPHM) correct?
分析师对Reneo PharmPharmticals(RPHM)的评级正确吗？
While ratings are subjective and will change, the latest Reneo Pharmaceuticals (RPHM) rating was a reiterated with a price target of $0.00 to $30.00. The current price Reneo Pharmaceuticals (RPHM) is trading at is $8.21, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Reneo PharmPharmticals(RPHM)评级被重申，目标价在0.00美元至30.00美元之间。雷诺制药(Reneo PharmPharmticals)目前的交易价格为8.21美元，在分析师的预测范围内。